All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMG-20
Therapeutic Area: Dermatology Product Name: IMG-20
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Vertex Ventures
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 09, 2020
Details:
The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. IMG-20, Inmagene’s most advanced drug candidate, is about to enter the global registration trials for multiple indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
CBP-201 is a potent monoclonal antibody against IL-4Rα. Data support further evaluation of CBP-201’s effects in an ongoing dose-ranging study in patients with moderate-to-severe AD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SHR0302
Therapeutic Area: Dermatology Product Name: SHR0302
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance. Several late stage clinical studies are on-going in Ulcerative Colitis, Crohn's disease, etc.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
The study conducted in ten sites in Australia and New Zealand, evaluated the efficacy and safety of CBP-201 in 31 patients with moderate-to-severe AD who have had inadequate response to topical corticosteroids and immunosuppressants.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 24, 2020
Details:
The company plans to use the proceeds to support the ongoing Phase 2 clinical trial for CBP-201; Phase 2 trials of CBP-307; expand the CBP-201 clinical development program into additional indications; and to support planned Phase 3 trials of CBP-201 and CBP-307.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
CBP-201 is a novel IL-4Rα antibody that, in a Phase 1b trial, demonstrated an efficacy profile superior to data from clinical studies of the current standard of care therapy for AD after four weeks of treatment.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
